SLC6A14 and neoplasm: So SLC6A14 can be a target in cancer treatment, either by blocking the transporter with α-MT, what results in an arrest of cells at G1/G0 stage, amino acid deprivation and autophagy, or by affecting tumor-associated immune cells (Karunakaran et al., 2008, 2011).